Koshinski Asset Management Inc. purchased a new position in shares of Chimerix, Inc. (NASDAQ:CMRX) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 35,486 shares of the biopharmaceutical company’s stock, valued at approximately $2,066,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Lindbrook Capital LLC bought a new stake in Chimerix during the 4th quarter worth approximately $31,000. SG Americas Securities LLC bought a new stake in Chimerix during the 4th quarter worth approximately $49,000. ProShare Advisors LLC bought a new stake in Chimerix during the 4th quarter worth approximately $52,000. HighTower Advisors LLC bought a new stake in Chimerix during the 4th quarter worth approximately $58,000. Finally, Strs Ohio bought a new stake in Chimerix during the 4th quarter worth approximately $87,000. Institutional investors and hedge funds own 45.41% of the company’s stock.
In related news, insider David Jakeman sold 3,211 shares of the firm’s stock in a transaction on Thursday, January 28th. The stock was sold at an average price of $8.61, for a total transaction of $27,646.71. Following the sale, the insider now owns 96,906 shares of the company’s stock, valued at approximately $834,360.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 9.00% of the company’s stock.
NASDAQ:CMRX opened at $8.75 on Thursday. Chimerix, Inc. has a 12-month low of $1.37 and a 12-month high of $11.57. The firm has a market capitalization of $749.69 million, a P/E ratio of -15.35 and a beta of 1.88. The stock’s fifty day simple moving average is $9.73 and its 200-day simple moving average is $6.22.
Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.01. Chimerix had a negative return on equity of 36.57% and a negative net margin of 321.31%. The business had revenue of $1.12 million for the quarter, compared to analyst estimates of $1.59 million. On average, sell-side analysts predict that Chimerix, Inc. will post -0.71 earnings per share for the current year.
Chimerix, Inc, a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients.
Read More: What member countries make up the G-20?
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRX).
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.